Article successfully added.

CyFlow™ CD180 Low Endotoxin

CyFlow™ CD180 Low Endotoxin
Alternative Name: Bgp95, Ly64, RP105
Antibody: Yes
Antigen: CD180
Application: Flow cytometry, Functional assays, Immunoprecipitation
Clonality: monoclonal
Clone: G28-8
Field of Interest: Immunophenotyping
Format/Fluorochrome: Low Endotoxin
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CP389435

For Research Use Only

$130.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
Close menu
CyFlow™ CD180 Low Endotoxin
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenHuman tonsillar B cells
Background InformationCD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. Its cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size.
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA: Antibody to a novel 95‑kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 1988 Jun 15; 140(12):4071‑8. < PMID: 3259604 > | Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, Valentine MA: Activation of human B cells: Comparison of the signal transduced by IL‑4 to fourdifferent competence signals. J Immunol. 1989 Dec 15; 143(12):3873‑80. < PMID: 2480376 > | Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis. 2001 Dec; 60(12):1137‑40. < PMID: 11709456 > | Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA: Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol. 2003 Jun 15; 170(12):6065‑72. < PMID: 12794135 > | Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the toll‑like receptor RP105 signaling in B lymphocytes. Blood. 2003 Aug 15; 102(4):1374‑80. < PMID: 12714520 > | Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL: Negative regulation of Toll‑like receptor 4 signaling by the Toll‑like receptor homolog RP105. Nat Immunol. 2005 Jun; 6(6):571‑8. < PMID: 15852007 > | Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol. 2007 Aug; 82(2):265‑71. < PMID: 17470533 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet